Unlock instant, AI-driven research and patent intelligence for your innovation.

Combination therapy of STING agonists and engineered immune cells

An immune cell, engineered technology, applied in the field of biomedicine, which can solve problems such as low response rate and limit the effectiveness and durability of CAR-T cell therapy

Active Publication Date: 2020-10-02
NANJING BIOHENG BIOTECH CO LTD
View PDF9 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the complexity of the tumor microenvironment, some patients with hematological tumors and solid tumors have a low response rate to CAR-T therapy, which limits the effectiveness and durability of CAR-T cell therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy of STING agonists and engineered immune cells
  • Combination therapy of STING agonists and engineered immune cells
  • Combination therapy of STING agonists and engineered immune cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0025] Unless otherwise specified, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0026] chimeric antigen receptor

[0027] As used herein, the term "chimeric antigen receptor" or "CAR" refers to an artificially constructed hybrid polypeptide that generally includes a ligand-binding domain (such as an antigen-binding portion of an antibody), a transmembrane domain, The co-stimulatory domain and the intracellular signaling domain are connected by linkers. CARs are able to exploit the antigen-binding properties of monoclonal antibodies to redirect the specificity and reactivity of T cells and other immune cells to a target of choice in a non-MHC-restricted manner. Non-MHC-restricted antigen recognition confers on CAR-expressing T cells the ability to recognize antigens independently of antigen processing, thus bypassing major mechanisms of tumor escape. Furthermo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of engineered immune cells expressing chimeric antigen receptors in combination with a STING agonist for the treatment of a disease, such as cancer, infectionor autoimmune disease. The addition of a STING agonist enhances the tumor killing activity of the immune cells without any adverse effect on their proliferation efficiency compared to the use of engineered immune cells expressing chimeric antigen receptors alone.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of the combination of STING agonist and engineered immune cells in treating diseases. Background technique [0002] Traditional tumor treatment methods include surgery, radiotherapy and chemotherapy. Cellular immunotherapy is an emerging tumor treatment method, among which recombinant chimeric antigen receptor cell therapy has been applied clinically and achieved significant therapeutic effects. [0003] Recombinant chimeric antigen receptor (CAR) cell therapy generally includes the following steps: extract immune system lymphocytes, such as T cells, from the patient's own body, and then culture and transform them in vitro to equip these T cells with extracellular tumors The specific antigen recognition domain and the intracellular signaling domain enable them to recognize and attack specific cancer cells, and then reinfuse the modified T cells to the patient...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K39/00A61P35/00A61P35/02A61P31/00A61P37/02A61P31/12A61P31/04A61P31/10A61P33/00A61P3/10A61P1/00A61P5/16A61P29/00A61P25/00A61P17/06A61P19/02A61P21/04A61P9/14A61P7/06
CPCA61K39/0011A61K45/06A61K2039/5156A61K2039/5158A61P1/00A61P3/10A61P5/16A61P7/06A61P9/14A61P17/06A61P19/02A61P21/04A61P25/00A61P29/00A61P31/00A61P31/04A61P31/10A61P31/12A61P33/00A61P35/00A61P35/02A61P37/02A61K2300/00
Inventor 邢芸闫忠辉任江涛贺小宏王延宾韩露
Owner NANJING BIOHENG BIOTECH CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com